GlassScriptPhysician profile
Steven R Weasen
NPI 1104880699
$1,627.05
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $414 · 2020: $180 · 2021: $524 · 2022: $491 · 2023: $17.42.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $17.42.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $17.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $527.51 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $352.55 | 2019-2022 | |
| Abbvie INC. | $160.47 | 2019-2023 | Skyrizi |
| Genzyme Corporation | $129.65 | 2021-2022 | |
| Pfizer INC. | $70.60 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $62.43 | 2019-2022 | |
| Amgen INC. | $59.60 | 2021-2022 | |
| Lilly USA, LLC | $56.03 | 2019-2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $51.15 | 2021 | |
| Dermira, INC. | $35.48 | 2020 | |
| Leo Pharma INC. | $31.97 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $23.49 | 2020 | |
| Almirall LLC | $23.13 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $15.34 | 2022 | |
| Biofrontera INC. | $14.77 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $12.88 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Weasen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.